rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Daniel D. Burgess

Director

Company insider

Files Form 4 as: Director, Cidara Therapeutics; Director, Arbutus Biopharma; Director, Nabriva Therapeutics; Director, Nabriva Therapeutics; Director, Santarus; Director, Metabasis Therapeutics; COO/CFO, Hollis Eden Pharmaceuticals Inc /de/.

Every Form 4 they filed

In numbers

Trades disclosed
107
Buys
2
Sells
8
Bought
$147K
Sold
$683K
Companies
7
Companies where not an officer
6
First trade
13 Feb 2006
Last trade
7 Jan 2026
Last filed
7 Jan 2026

Companies traded

Where they are an officer
Hollis Eden Pharmaceuticals Inc /de/Officer · last 14 Feb 20070 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
Cidara TherapeuticsDirector · Biotechnology · last 7 Jan 20261 buy · 0 sells
ABUS Arbutus BiopharmaDirector · Biotechnology · last 23 May 20240 buys · 0 sells
Nabriva TherapeuticsDirector · last 2 Aug 20221 buy · 2 sells
Nabriva TherapeuticsDirector · last 23 Jun 20170 buys · 0 sells
SantarusDirector · last 2 Jan 20140 buys · 5 sells
Metabasis TherapeuticsDirector · last 23 Jun 20090 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
7 Jan 2026filed 7 Jan 2026Cidara TherapeuticsBiotechnologySEC FORM 4 Code D$33K150 at $221.50filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—2,125filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,500filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—11,100filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—450filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—450filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—1,400filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—2,125filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—2,125filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—20,500filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—11,100filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—875filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed10

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.